CRISPR Clinical Trial Update
Apr. 21, 2021
Anjie Biomedical Technology
Main focus: Next generation CAR-T cells
Company stage: Clinical
Diseases: Solid tumors
Genome editing tool: CRISPR-Cas9
Funding stage: Private
Location: Guanzhou, China
Anjie Biomedical Technology develops next generation CAR-T cells for solid tumor treatment. The company uses CRISPR to knock out PD-1 from its CAR-T cell products, in order to optimize efficiacy and safety.
